Nelson Dusetti: Understanding the cellular mechanisms that drive pancreatic cancer treatment resistance in advanced cases

Nelson Dusetti shared on LinkedIn:

“We are deeply grateful to the National Cancer Institute  for awarding us the ‘Call for projects PRT-K 2024 Translational Research Program in Cancerology INCa-DGOS’ funding. This vital support will enable us to study the evolution of pancreatic cancers following treatment, with a focus on understanding the cellular mechanisms that drive treatment resistance in advanced cases. This knowledge will be key to developing strategies to overcome or prevent resistance through personalized therapies.

This type of funding is essential in strengthening and advancing the close collaboration between the CRCM – Marseille Cancer Research Center and the Paoli-Calmettes Institute, enriching translational research and bringing scientific solutions directly to the benefit of patients.”

Read further.
Source: Nelson Dusetti/LinkedIn

Nelson Dusetii is the Scientific Director of the company Predicting Med (CSO) and Chair of TRANSLATE-IT CRCM. He is also research director at INSERM. He is the Head of the Department of Translational Research and Innovative Therapies at CRCM.